Biz News Today

Bristol-Myers Squibb National Survey Finds a Disparity Between Health Care Providers and HIV Positive Patients Perspectives on the Emotional Barriers to Seeking HIV Care and Treatment

July 22, 2010

Original Source

Bristol-Myers Squibb Second Quarter Featured Robust Clinical Data and Double-Digit EPS Growth

July 22, 2010

Original Source

Bristol-Myers Squibb to Announce Results for Second Quarter 2010 on July 22

July 13, 2010

Original Source

SPRYCEL® (dasatinib) Receives FDA Priority Review for the Treatment of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase

July 9, 2010

Original Source

Dapagliflozin As Add On Therapy To Insulin Demonstrated Improved Glycemic Control in Patients With Type 2 Diabetes Inadequately Controlled With Insulin

June 26, 2010

Original Source

52-Week Study Finds ONGLYZA™ (saxagliptin) When Added to Metformin Was Non-Inferior to Titrated Glipizide When Added to Metformin in Reducing Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus

June 26, 2010

Original Source

ONGLYZA™ (saxagliptin) With Metformin as Initial Combination Therapy Provided 76-Week Long-Term Glycemic Control in Treatment-Naïve Adults With Type 2 Diabetes

June 26, 2010

Original Source

Dapagliflozin as Monotherapy Demonstrated Improved Glycemic Control in Treatment-Naïve Adults with Type 2 Diabetes

June 22, 2010

Original Source

Bristol-Myers Squibb to Present at the 2010 Wells Fargo Securities Health Care Conference

June 16, 2010

Original Source

New Data for Investigational Antibody Blocking IL-6 in Rheumatoid Arthritis Patients to be Presented at Annual Congress of European League Against Rheumatism

June 15, 2010

Original Source

Bristol-Myers Squibb Signs Agreements with ICON and PAREXEL to Support Greater Efficiencies in Clinical Development

June 14, 2010

Original Source

AVERROES Study of Investigational Agent Apixaban Closes Early Due to Clear Evidence of Efficacy

June 10, 2010

Original Source

Bristol-Myers Squibb Announces Dividend

June 9, 2010

Original Source

Bristol-Myers Squibb Posts Data Update on BMS-901608, an anti-CS-1 Antibody Under Investigation for the Treatment of Multiple Myeloma

June 8, 2010

Original Source

Bristol-Myers Squibb to Present at the Goldman Sachs Global Health Care Conference

June 8, 2010

Original Source

Four-Year Follow-Up Data for SPRYCEL® (dasatinib) Demonstrate 82 Percent Overall Survival in Patients with Chronic Myeloid Leukemia Who Failed Gleevec®1

June 7, 2010

Original Source

SPRYCEL® (dasatinib) Demonstrates Superior Confirmed Complete Cytogenetic Response Rates Compared to Gleevec®* in Study of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

June 5, 2010

Original Source

Investigational Compound Ipilimumab Demonstrates Improved Overall Survival in Phase 3 Trial of Previously-Treated Patients with Metastatic Melanoma

June 5, 2010

Original Source

Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights

May 27, 2010

Original Source

Controlled Phase 2 Study of Ipilimumab Shows Clinical Activity in Advanced Non-Small Cell Lung Cancer

May 21, 2010

Original Source

Bristol-Myers Squibb National Survey Finds a Disparity Between Health Care Providers and HIV Positive Patients Perspectives on the Emotional Barriers to Seeking HIV Care and Treatment

Bristol-Myers Squibb Second Quarter Featured Robust Clinical Data and Double-Digit EPS Growth

Bristol-Myers Squibb to Announce Results for Second Quarter 2010 on July 22

SPRYCEL® (dasatinib) Receives FDA Priority Review for the Treatment of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase

Dapagliflozin As Add On Therapy To Insulin Demonstrated Improved Glycemic Control in Patients With Type 2 Diabetes Inadequately Controlled With Insulin

52-Week Study Finds ONGLYZA™ (saxagliptin) When Added to Metformin Was Non-Inferior to Titrated Glipizide When Added to Metformin in Reducing Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus

ONGLYZA™ (saxagliptin) With Metformin as Initial Combination Therapy Provided 76-Week Long-Term Glycemic Control in Treatment-Naïve Adults With Type 2 Diabetes

Dapagliflozin as Monotherapy Demonstrated Improved Glycemic Control in Treatment-Naïve Adults with Type 2 Diabetes

Bristol-Myers Squibb to Present at the 2010 Wells Fargo Securities Health Care Conference

New Data for Investigational Antibody Blocking IL-6 in Rheumatoid Arthritis Patients to be Presented at Annual Congress of European League Against Rheumatism

Bristol-Myers Squibb Signs Agreements with ICON and PAREXEL to Support Greater Efficiencies in Clinical Development

AVERROES Study of Investigational Agent Apixaban Closes Early Due to Clear Evidence of Efficacy

Bristol-Myers Squibb Announces Dividend

Bristol-Myers Squibb Posts Data Update on BMS-901608, an anti-CS-1 Antibody Under Investigation for the Treatment of Multiple Myeloma

Bristol-Myers Squibb to Present at the Goldman Sachs Global Health Care Conference

Four-Year Follow-Up Data for SPRYCEL® (dasatinib) Demonstrate 82 Percent Overall Survival in Patients with Chronic Myeloid Leukemia Who Failed Gleevec®1

SPRYCEL® (dasatinib) Demonstrates Superior Confirmed Complete Cytogenetic Response Rates Compared to Gleevec®* in Study of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Investigational Compound Ipilimumab Demonstrates Improved Overall Survival in Phase 3 Trial of Previously-Treated Patients with Metastatic Melanoma

Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights

Controlled Phase 2 Study of Ipilimumab Shows Clinical Activity in Advanced Non-Small Cell Lung Cancer

Biz News Today Accepts Guest Posts

Recommended Sites